Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

903 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Multicenter validation study of anti-programmed cell death-1 antibody as a serological marker for type 1 autoimmune hepatitis.
Miyake Y, Yamamoto K, Matsushita H, Abe M, Takahashi A, Umemura T, Tanaka A, Nakamuta M, Nakamoto Y, Ueno Y, Saibara T, Takikawa H, Yoshizawa K, Ohira H, Zeniya M, Onji M, Tsubouchi H; Intractable Hepato-Biliary Disease Study Group of Japan. Miyake Y, et al. Among authors: nakamoto y. Hepatol Res. 2014 Dec;44(13):1299-307. doi: 10.1111/hepr.12305. Epub 2014 Mar 6. Hepatol Res. 2014. PMID: 24506172
Guideline on the use of new anticancer drugs for the treatment of Hepatocellular Carcinoma 2010 update.
Kaneko S, Furuse J, Kudo M, Ikeda K, Honda M, Nakamoto Y, Onchi M, Shiota G, Yokosuka O, Sakaida I, Takehara T, Ueno Y, Hiroishi K, Nishiguchi S, Moriwaki H, Yamamoto K, Sata M, Obi S, Miyayama S, Imai Y. Kaneko S, et al. Among authors: nakamoto y. Hepatol Res. 2012 Jun;42(6):523-42. doi: 10.1111/j.1872-034X.2012.00981.x. Hepatol Res. 2012. PMID: 22568457
The prognosis of hepatitis B inactive carriers in Japan: a multicenter prospective study.
Taida T, Arai M, Kanda T, Hige S, Ueno Y, Imazeki F, Izumi N, Tanaka E, Shinkai N, Yoshioka K, Nakamoto Y, Nishiguchi S, Tsuge M, Abe M, Sata M, Yatsuhashi H, Ido A, Kita K, Azemoto R, Kitsukawa Y, Goto N, Yokosuka O. Taida T, et al. Among authors: nakamoto y. J Gastroenterol. 2017 Jan;52(1):113-122. doi: 10.1007/s00535-016-1229-6. Epub 2016 Jun 15. J Gastroenterol. 2017. PMID: 27306374
Sofosbuvir plus velpatasvir treatment for hepatitis C virus in patients with decompensated cirrhosis: a Japanese real-world multicenter study.
Tahata Y, Hikita H, Mochida S, Kawada N, Enomoto N, Ido A, Yoshiji H, Miki D, Hiasa Y, Takikawa Y, Sakamori R, Kurosaki M, Yatsuhashi H, Tateishi R, Ueno Y, Itoh Y, Yamashita T, Kanto T, Suda G, Nakamoto Y, Kato N, Asahina Y, Matsuura K, Terai S, Nakao K, Shimizu M, Takami T, Akuta N, Yamada R, Kodama T, Tatsumi T, Yamada T, Takehara T. Tahata Y, et al. Among authors: nakamoto y. J Gastroenterol. 2021 Jan;56(1):67-77. doi: 10.1007/s00535-020-01733-4. Epub 2020 Oct 1. J Gastroenterol. 2021. PMID: 33001338 Clinical Trial.
Hepatocellular carcinoma development in diabetic patients: a nationwide survey in Japan.
Tateishi R, Matsumura T, Okanoue T, Shima T, Uchino K, Fujiwara N, Senokuchi T, Kon K, Sasako T, Taniai M, Kawaguchi T, Inoue H, Watada H, Kubota N, Shimano H, Kaneko S, Hashimoto E, Watanabe S, Shiota G, Ueki K, Kashiwabara K, Matsuyama Y, Tanaka H, Kasuga M, Araki E, Koike K; LUCID study investigators. Tateishi R, et al. J Gastroenterol. 2021 Mar;56(3):261-273. doi: 10.1007/s00535-020-01754-z. Epub 2021 Jan 11. J Gastroenterol. 2021. PMID: 33427937 Free PMC article.
Clinical practice guidelines for autoimmune hepatitis.
Ohira H, Takahashi A, Zeniya M, Abe M, Arinaga-Hino T, Joshita S, Takaki A, Nakamoto N, Kang JH, Suzuki Y, Sogo T, Inui A, Koike K, Harada K, Nakamoto Y, Kondo Y, Genda T, Tsuneyama K, Matsui T, Tanaka A. Ohira H, et al. Among authors: nakamoto y, nakamoto n. Hepatol Res. 2022 Jul;52(7):571-585. doi: 10.1111/hepr.13776. Epub 2022 May 25. Hepatol Res. 2022. PMID: 35533021 No abstract available.
Factors involved in gastroesophageal varix-related events in patients with hepatitis C virus-related compensated and decompensated cirrhosis after direct-acting antiviral therapy.
Tahata Y, Hikita H, Mochida S, Enomoto N, Kawada N, Ido A, Miki D, Kurosaki M, Yoshiji H, Sakamori R, Kuroda H, Yatsuhashi H, Yamashita T, Hiasa Y, Kato N, Miyaaki H, Ueno Y, Itoh Y, Matsuura K, Takami T, Asahina Y, Suda G, Akuta N, Tateishi R, Nakamoto Y, Kakazu E, Terai S, Shimizu M, Miyazaki M, Nozaki Y, Sobue S, Yano H, Miyaki T, Moriuchi A, Hori T, Shirai K, Murai K, Saito Y, Kodama T, Tatsumi T, Yamada T, Takehara T. Tahata Y, et al. Among authors: nakamoto y. Hepatol Res. 2024 Oct 29. doi: 10.1111/hepr.14131. Online ahead of print. Hepatol Res. 2024. PMID: 39470448
Liver-related events after direct-acting antiviral therapy in patients with hepatitis C virus-associated cirrhosis.
Tahata Y, Hikita H, Mochida S, Enomoto N, Kawada N, Kurosaki M, Ido A, Miki D, Yoshiji H, Takikawa Y, Sakamori R, Hiasa Y, Nakao K, Kato N, Ueno Y, Yatsuhashi H, Itoh Y, Tateishi R, Suda G, Takami T, Nakamoto Y, Asahina Y, Matsuura K, Yamashita T, Kanto T, Akuta N, Terai S, Shimizu M, Sobue S, Miyaki T, Moriuchi A, Yamada R, Kodama T, Tatsumi T, Yamada T, Takehara T. Tahata Y, et al. Among authors: nakamoto y. J Gastroenterol. 2022 Feb;57(2):120-132. doi: 10.1007/s00535-021-01845-5. Epub 2022 Jan 20. J Gastroenterol. 2022. PMID: 35059853
903 results